Related references
Note: Only part of the references are listed.Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study
Chun-Yuan Lee et al.
INFECTIOUS DISEASES AND THERAPY (2023)
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz plus lamivudine plus tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
Jing Cao et al.
BMC INFECTIOUS DISEASES (2023)
Immune response to ART initiation in advanced HIV infection
Karam Mounzer et al.
HIV MEDICINE (2023)
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
Ines Suarez-Garcia et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
Lee A. A. Evitt et al.
AIDS RESEARCH AND THERAPY (2023)
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Paul E. Sax et al.
ECLINICALMEDICINE (2023)
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Lisi Deng et al.
BMC INFECTIOUS DISEASES (2022)
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Olayemi Osiyemi et al.
CLINICAL INFECTIOUS DISEASES (2022)
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection
Pedro Cahn et al.
AIDS (2022)
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults
Ines Mendoza et al.
ANNALS OF PHARMACOTHERAPY (2022)
Metabolic Consequences of Antiretroviral Therapy
Caroline E. Diggins et al.
CURRENT HIV/AIDS REPORTS (2022)
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
Javier Martinez-Sanz et al.
FRONTIERS IN IMMUNOLOGY (2022)
Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study
Yang Tongtong et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)
Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World
Fang Zhao et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2022)
Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study
Raquel Martin-Iguacel et al.
ECLINICALMEDICINE (2022)
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naive HIV-1-infected adults
Jin Li et al.
MEDICINE (2022)
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment
Ashima Pyngottu et al.
CLINICAL INFECTIOUS DISEASES (2021)
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors
G. Schuettfort et al.
HIV MEDICINE (2021)
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment
Marta Rava et al.
AIDS (2021)
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance
Nokuzola Mbhele et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Rickesh Patel et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
Anthony T. Podany et al.
CLINICAL PHARMACOKINETICS (2020)
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Jean-Michel Molina et al.
LANCET HIV (2018)
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Eric S. Daar et al.
LANCET HIV (2018)
Patient-Reported Symptoms Over 48Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
David Wohl et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax et al.
LANCET (2017)
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel Gallant et al.
LANCET (2017)
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Manuel Tsiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)